Clinical Trials Directory

Trials / Recruiting

RecruitingNCT03916978

Autologous PRP Intra Ovarian Infusion to Restore Ovarian Function in Menopausal Women

Investigating Reactivation of Ovarian Function Following Autologous PRP Intra-ovarian Infusion in Menopausal Women

Status
Recruiting
Phase
Phase 2 / Phase 3
Study type
Interventional
Enrollment
100 (estimated)
Sponsor
Genesis Athens Clinic · Academic / Other
Sex
Female
Age
45 Years – 55 Years
Healthy volunteers
Accepted

Summary

Autologous PRP intra ovarian infusion may restore ovarian function, may promote folliculogenesis and may improve hormonal profile of women in menopause.

Detailed description

This triple-blind Randomized Controlled Trial (RCT) aims to investigate the effectiveness of autologous PRP intra ovarian infusion on reactivating ovarian functionality and on promoting folliculogenesis in regard to menopausal women. PRP is blood plasma prepared from fresh whole blood that has been enriched with platelets. It is collected from peripheral veins and contains several growth factors such as vascular endothelial growth factor (VEGF), epidermal growth factor (EGF), platelet derived growth factor (PDGF), transforming growth factor (TGF) and other cytokines all of which stimulate tissue proliferation and growth. PRP has been employed in several medical conditions in Orthopedics, Dermatology, and Ophthalmology for wound healing. It's efficacy in ovarian rejuvenation and reactivation and endometrial regeneration has not been fully elucidated. This study aims to investigate the effect of autologous PRP intra ovarian infusion on restoring ovarian tissue functionality in menopausal women.

Conditions

Interventions

TypeNameDescription
BIOLOGICALAutologous PRP intra ovarian infusionAutologous PRP intra ovarian infusion
BIOLOGICALAutologous PFP intra ovarian infusionAutologous PFP intra ovarian infusion

Timeline

Start date
2019-05-21
Primary completion
2026-01-30
Completion
2026-07-30
First posted
2019-04-16
Last updated
2024-12-27

Locations

1 site across 1 country: Greece

Source: ClinicalTrials.gov record NCT03916978. Inclusion in this directory is not an endorsement.